Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

9.38
+0.10001.08%
Post-market: 9.380.00000.00%18:50 EDT
Volume:664.56K
Turnover:6.28M
Market Cap:512.90M
PE:-5.03
High:9.62
Open:9.35
Low:9.28
Close:9.28
Loading ...

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

GlobeNewswire
·
17 Apr

BRIEF-Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher

Reuters
·
07 Apr

Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves

MT Newswires Live
·
07 Apr

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

THOMSON REUTERS
·
07 Apr

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

GlobeNewswire
·
07 Apr

Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor

MT Newswires Live
·
01 Apr

Zevra Therapeutics: Confirms Receipt of Two Director Nominees From Daniel J. Mangless

THOMSON REUTERS
·
01 Apr

Zevra Therapeutics Files Preliminary Proxy

THOMSON REUTERS
·
01 Apr

Zevra Therapeutics Files Preliminary Proxy

GlobeNewswire
·
01 Apr

Zevra Therapeutics management to meet with Cantor Fitzgerald

TIPRANKS
·
26 Mar

John Bode Bought 33% More Shares In Zevra Therapeutics

Simply Wall St.
·
23 Mar

Top Executive Makes Bold Move with Major Stock Purchase in Zevra Therapeutics!

TIPRANKS
·
22 Mar

Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves

TIPRANKS
·
14 Mar

Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
14 Mar

Zevra Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
13 Mar

Zevra Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
13 Mar

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

GuruFocus.com
·
12 Mar

Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating

TIPRANKS
·
12 Mar

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
12 Mar